INC Research's Chairman and CEO James Ogle Selected for PharmaVOICE 100
(Thomson Reuters ONE) -
Chairman and Chief Executive Officer Honored for Leadership and Success though
Pivotal Year for Global Clinical Research Organization
Raleigh, NC, Aug. 1 - INC Research, LLC, a therapeutically focused clinical
research organization (CRO) with a Trusted Process® for delivering reliable
results, is pleased to announce Chairman and Chief Executive Officer James Ogle
has been named to the annual PharmaVOICE 100 as one of the top driving forces in
the life sciences industry. Under his leadership, INC Research acquired Kendle
International, AVOS Consulting and Trident Clinical Research in a single
calendar year, more than doubling the size of the Company. Despite the
transformational nature of the acquisitions, INC Research successfully
integrated operations while maintaining its focus on delivering the highest
standards of quality and value to its customers.
Ogle has served as CEO of INC Research since 2003 and has more than two decades
of experience in the CRO and biopharmaceutical industries. His outstanding
leadership skills have been reflected in the transformation of INC Research into
a top-tier global CRO, as demonstrated by the rapid and efficient completion of
integration of three companies that greatly enhanced the Company's global
profile in only 12 months.
During this same timeframe, the Company has continued to win awards for quality,
consistency and delivery. In February, the 2012 CRO Quality Benchmarking Report
from Industry Standard Research found INC Research had "the most consistent
quality ratings of all of the companies we profiled, and their customers are
very satisfied."
"The standards Jim sets and maintains for our global team ensure we follow
through on our Trusted Process methodology to deliver consistent, repeatable
results to the biopharmaceutical industry," said INC Research Chief Operating
Officer Jamie Macdonald.
Known by his staff as a quick adopter, Ogle has stayed ahead of the curve with
developments in technology. "Long before the metrics-driven dashboards common in
the industry today, INC Research was collecting and analyzing metrics to help us
improve delivery and customer satisfaction," said Senior Vice President,
Corporate Development, Jean Chitwood. "That was all powered by Jim's view that
the CRO industry is, at its heart, driven by strong project management."
Above all else, Ogle is recognized for his outstanding leadership skills, which
have attributed to a cohesive team unit at INC Research. After completing a
distinguished military career in which he achieved the rank of Lieutenant
Colonel, United States Army, Ogle brought his timeless leadership approach to
all facets of his profession. His staff is inspired by his ability to maintain
the highest level of personal integrity and credibility, both of which have been
driving forces behind the Company becoming an award-winning CRO.
"Jim uses strong emotional intelligence and surrounds himself with self-directed
leaders that can absorb and follow his vision," explained INC Research Chief
Information Officer Bill Pierce. "His big ideas and visions have matured and the
result is a company that has moved into the top tier of our industry. Jim
executes on what he believes, attracts the best and uses professionalism and
innovation as the hallmark of how we serve our customers."
Featured in the July/August 2012 issue of PharmaVOICE, Ogle was selected from a
group of nominations submitted by readers. A panel of PharmaVOICE editors
evaluated the submissions based on the individual's ability to inspire, motivate
and influence corporate leadership, research and development, technology,
creativity, marketing, and strategy.
About PharmaVOICE
PharmaVOICE is expressly written and designed to deliver the views, opinions,
and insights of executives who are shaping the direction of the dynamic life-
sciences industry. PharmaVOICE reaches more than 17,500 readers every month in
print and 70,000 with its digital edition.
PharmaVOICE's unique horizontal editorial approach cuts across industry silos,
providing a holistic overview of the life-sciences industry, addressing a range
of topics from molecule through market. By engaging compelling personalities
from diverse industry sectors, PharmaVOICE provides multiple perspectives on
business challenges, trends, and topics. Editorial content sparks dialog,
initiates debate, and opens the lines of communication to facilitate and improve
business-to-business relationships.
About INC Research
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conducting global clinical
development programs of the highest integrity. Pharmaceutical and biotechnology
companies look to INC Research for a complete range of customized Phase I
through Phase IV programs in all therapeutic areas and innovative pediatric and
women's health trials. The company's Trusted Process(®) methodology and
therapeutic foresight lead customers to more confident, better-informed drug and
device development decisions. INC Research is headquartered in Raleigh, NC. For
more information, please visit www.incresearch.com or follow us
at (at)inc_research.
Contact: Lori Dorer, Media (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
[HUG#1631260]
Unternehmensinformation / Kurzprofil:
Datum: 01.08.2012 - 19:18 Uhr
Sprache: Deutsch
News-ID 170871
Anzahl Zeichen: 6336
contact information:
Town:
Raleigh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 594 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"INC Research's Chairman and CEO James Ogle Selected for PharmaVOICE 100"
steht unter der journalistisch-redaktionellen Verantwortung von
INC RESEARCH, LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
